Abstract
Behçet’s syndrome is an autoinflammatory disease of uncertain cause characterized by mucous membrane ulceration, arthritis and inflammation within most tissues. Its prevalence differs throughout different populations, but neurological complications arise in 10 % of all those affected. The majority develop inflammation within the central nervous system which may remit but may also progressively worsen without treatment. This article reviews the epidemiology, clinical characteristics, natural history and management of the disorders, and emphasizes recent considerable advances in our understanding of the various treatments which may be beneficial across the spectrum of disease types.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
• Yazici H, Fresko I, Yurdukal S. Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007; 3:148–55. This is the best review on systemic manifestations of the disease published to date.
Yamamoto SI, Toykawa H, Matsubara J, et al. A nationwide survey of Behçet’s disease in Japan. I. Epidemiological survey. Jpn J Ophthalmol. 1974;18:282–90.
Yurdukal S, Gunaydin I, Tuzun Y, Tankurt N, Parzarli H, Ozyazgan Y, et al. The prevalence of Behçet’s syndrome in a rural area in Northern Turkey. J Rheumatol. 1988;15:820–2.
Kidd D. An epidemiological survey of Behçet’s syndrome and its neurological complications in Hertfordshire, UK. Adv Exp Med Biol. 2003;528:95–7.
Serdaroglu P, Yazici H, Ozdemir C, Yurdakul S, Bahar S, Atkin E. Neurologic involvement in Behçet’s syndrome: a prospective study. Arch Neurol. 1989;46:265–9.
• Al Araji A, Kidd D. Neuro-Behcet’s disease: epidemiology, clinical characteristics and management. Lancet Neurol. 2009;8:192–204. The most comprehensive study of neurological manifestations published to date.
Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behçet’s syndrome: a review of Japanese autopsy registry data. Hum Pathol. 1985;16:790–5.
Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behçet’s syndrome. Brain. 1999;122:2181–94.
Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. Brain. 1999;122:2171–80.
Al-Fahad SA, Al-Araji AH. Neuro-Behçet’s disease in Iraq: a study of 40 patients. J Neurol Sci. 1999;170:105–11.
Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248:95–103.
Ideguchi H, Suda A, Takeno M, Ihata A, Ueda A, Ohno S, et al. Neurological manifestations of Behçet’s disease in Japan: a study of 54 patients. J Neurol. 2010;257:1012–20.
Shimojo S, Yamamoto N, Matsuda T, Yuinari T. Asymptomatic neuro-Behçet’s disease. J Neuroimaging. 1998;8:59–60.
Yesilot N, Shehu M, Oktem-Tonor O, Serdaroglu P, Akman-Demir G. Silent neurological involvement in Behçet’s disease. Clin Exp Rheumatol. 2006;24 Suppl 42:S65–70.
Bousser MG, Bletry O, Launay M, Portier E, Giullard A, Castaigne P. Thromboses veineuses cerebrales au cours de la maladie de Behcet. Rev Neurol. 1980;136:753–62.
Wechsler B, Vidaihet M, Piette PC, Bousser MG, Dell Isola B, Bletry O, et al. Cerebral venous sinus thrombosis in Behçet’s disease; clinical study and long term follow up of 25 cases. Neurology. 1992;42:614–18.
• Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behçet’s disease: a systematic review. J Neurol. 2011;258:719–27. This is an important study which helps to define the treatment of this manifestation of the disease; physicians inexperienced in the management of the condition find it difficult to decide on optimum therapy.
Lee SH, Yoon PH, Park SJ, Kim DI. MRI findings in neuro-Behçet’s disease. Clin Radiol. 2001;56:485–94.
Alkan A, Goktan A, Karincaoglu Y, Kamisli S, Dogan M, Oztanir N, et al. Brain perfusion MRI findings in patients with Behçet’s disease. ScientificWorldJournal. 2012;2012:261502.
Kang DW, Chu K, Cho JY, Koo JS, Yoon BW, Roh JK, et al. Diffusion-weighted MRI in neuro-Behçet’s disease. J Neurol Neurosurg Psychiatry. 2001;70:412–3.
Coban O, Bahar S, Akman-Demir G, Tasci G, Yudakul S, Yazici H, et al. Masked assessment of MRI findings: is it possible to differentiate neuro-Behçet’s disease from other central nervous system diseases? Neuroradiology. 1999;41:255–60.
Sarhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P. Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol. 2003;145:127–34.
Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, et al. Cerebrospinal fluid interleukin-6 in progressive neuro-Behçet’s syndrome. Clin Immunol Immunopathol. 1997;82:12–7.
de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic risk association studies. Arthritis Rheum. 2009;61:1287–96.
Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behçet’s disease clinical characteristics: systematic review and mate-analysis of observational studies. Rheumatology (Oxford). 2012;51:887–900.
Hadfield MG, Aydin F, Lippman HR, Kubal WS, Sanders KM. Neuro-Behçet’s disease. Clin Neuropathol. 1996;15:249–55.
Arai Y, Kohno S, Takahashi Y, Miyajima Y, Tsutsui Y. Autopsy case of neuro-Behçet’s disease with multifocal neutrophilic perivascular inflammation. Neuropathology. 2006;26:579–85.
Hirohata S. Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Si. 2008;267:41–7.
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. Management of Behçet’s disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behçet’s disease. Ann Rheum Dis. 2008;67:1656–62.
Ait Ben Haddou EH, Imounan F, Regragui W, Mouti O, Benchakroune N, Abouqal R, et al. Neurological manifestations of Behçet’s disease: evaluation of 40 patients treated by cyclophosphamide. Rev Neurol (Paris). 2012;168:344–9.
Piptone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Behçet’s disease: a case series and literature review. Arthritis Rheum. 2008;59:285–90.
• Giardina A, Ferrante A, Ciccia F, Vadala M, Giardina E, Triolo G. One year study of the efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs. Rheumatol Int. 2011;31:33–7. This study is an important assessment of the most modern forms of treatment of severe manifestations of the disease.
Olivieri I, Leccese P, D’Angelo S, Padula A, Nigro A, Palazzi C, et al. Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29 Suppl 67:S54–57.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kidd, D. Neurological Complications of Behçet’s Syndrome. Curr Neurol Neurosci Rep 12, 675–679 (2012). https://doi.org/10.1007/s11910-012-0316-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-012-0316-1